Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

Salvage or delayed autologous stem cell transplantation (ASCT) has historically been an important treatment option for relapsed/refractory multiple myeloma (RRMM). However, its role has been challenged in recent years with the emergence of highly active T-cell–redirecting therapies, including bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy [ 1 ]. Despite these advances, salvage ASCT remains a valuable alternative for inducing deep and durable remissions in well-selected patients, although relapse ultimately occurs in most cases [ 2 ].